¹⁷⁷Lu-PSMA-617 versus a change of androgen receptor pathway inhibitor therapy for taxane-naive patients with progressive metastatic castration-resistant prostate cancer (PSMAfore): a phase 3, randomised, controlled trial

Prof Michael J Morris, MD^a,*morrism@mskcc.org ∙ Daniel Castellano, MD^b ∙ Prof Ken Herrmann, MD^c,d ∙ Prof Johann S de Bono, FRCP^e ∙ Neal D Shore, FACS^f ∙ Prof Kim N Chi, MD^g ∙ Michael Crosby, MS^h ∙ Josep M Piulats, MDⁱ ∙ Aude Fléchon, MD^j ∙ Xiao X Wei, MD^k ∙ Hakim Mahammedi, MD^l ∙ Guilhem Roubaud, MD^m ∙ Hana Študentová, PhDⁿ ∙ Prof James Nagarajah, MD^o,p ∙ Begoña Mellado, MD^q ∙ Álvaro Montesa-Pino, MD^r ∙ Euloge Kpamegan, PhD^s ∙ Samson Ghebremariam, PhD^s ∙ Teri N Kreisl, MD^s ∙ Celine Wilke, MD^t ∙ Katja Lehnhoff, PhD^t ∙ Prof Oliver Sartor, MD^u,* ∙ Prof Karim Fizazi, MD^v,* for the PSMAfore Investigators^†

[¹⁷⁷Lu]Lu-PSMA-617 (¹⁷⁷Lu-PSMA-617) prolongs radiographic progression-free survival and overall survival in patients with metastatic castration-resistant prostate cancer previously treated with androgen receptor pathway inhibitor (ARPI) and taxane therapy. We aimed to investigate the efficacy of ¹⁷⁷Lu-PSMA-617 in patients with taxane-naive metastatic castration-resistant prostate cancer.

 

Click here to read the article